Convergence Investment Partners LLC Has $2.45 Million Holdings in Cencora, Inc. $COR

Convergence Investment Partners LLC increased its stake in shares of Cencora, Inc. (NYSE:COR) by 31.6% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 7,789 shares of the company’s stock after acquiring an additional 1,869 shares during the period. Convergence Investment Partners LLC’s holdings in Cencora were worth $2,447,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. T. Rowe Price Investment Management Inc. raised its stake in Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after acquiring an additional 4,123,795 shares in the last quarter. Norges Bank bought a new position in shares of Cencora during the fourth quarter valued at $822,506,000. Marshall Wace LLP boosted its stake in shares of Cencora by 518.9% in the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after purchasing an additional 1,672,762 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Cencora by 528.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after purchasing an additional 1,241,186 shares in the last quarter. Finally, Viking Global Investors LP grew its holdings in shares of Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after purchasing an additional 1,013,913 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In other news, Director Lauren M. Tyler acquired 550 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director directly owned 4,359 shares in the company, valued at $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.38% of the stock is currently owned by insiders.

Cencora Stock Down 1.4%

NYSE:COR opened at $303.65 on Tuesday. The company has a market cap of $59.08 billion, a price-to-earnings ratio of 23.29, a P/E/G ratio of 1.71 and a beta of 0.58. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The stock’s fifty day moving average price is $280.85 and its two-hundred day moving average price is $317.26. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its Board of Directors has approved a stock repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to buy up to 3.9% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on COR. Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. UBS Group boosted their price target on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Evercore set a $360.00 price objective on shares of Cencora in a research note on Wednesday, April 8th. Wells Fargo & Company dropped their price objective on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Finally, Robert W. Baird cut their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.